Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.2805 -0.0145 (-4.92%)
Official Closing Price Updated: 8:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Taps Biotech Veteran to Lead Next Phase of Growth
Via Investor Brand Network
Celebrity Announcements of Breast Cancer Underscore Increasing Prevalence in Younger Women
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Unveils Promising Data on CLD-401 at ASCO 2025
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Korean Researchers Develop AI to Predict Cancer Patients’ Response to Immunotherapy
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc.’s (NYSE American: CLDI) RTNova Shows Promise in Targeted Tumor Therapy
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Names Experienced Life Science Leader as New CEO
Via Investor Brand Network
New Multimodal AI System Boosts the Accuracy of Lung Cancer Screening
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Redtail Virotherapy Platform and Reduces Q1 Losses
Via Investor Brand Network
Exposures Product Safety
Getting a Second Opinion After Breast Cancer Diagnosis Doesn’t Delay Treatment Commencement
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Eyes Game-Changing Approach to Cancer Treatment
Via Investor Brand Network
Study: Women with Lung Cancer Have Worse Outcomes Due to Genes Linked to Pregnancy
Via Investor Brand Network
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research
Via Investor Brand Network
Topics Death
Exposures Death
Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances RTNova Platform with IL15 Superagonist Payload
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Grants Inducement Stock Option to New CEO Eric Poma
Via Investor Brand Network
How Stem Cells Help in Blood Cancer Treatment
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Appoints Eric Poma as CEO to Lead Next Phase of Clinical Growth
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Host Investor Webinar Highlighting Cancer Immunotherapy Pipeline
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
Via Investor Brand Network
Portuguese Researchers Make Progress in Developing Immunotherapy Targeting Colorectal Cancer
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Receives FDA Clearance to Begin Trials for CLD-201 in Solid Tumors
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Advances Cancer Platforms, Reports Narrowed Loss for Q4 2024
Via Investor Brand Network
Study Explains Why Melanoma, Other Cancers Evade and Resist Immunotherapy
Via Investor Brand Network
InvestorNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs
Via Investor Brand Network
Natural Killer Cells That are Genetically Modified Show Potential in Cancer Immunotherapy
Via Investor Brand Network
BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces $3.9 Million Registered Direct Offering and Private Placement
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.